FDA Grants Calliditas Accelerated Approval Of Tarpeyo To Reduce Proteinuria In IgA Nephropathy

The U.S. Food and Drug Administration has approved Tarpeyo or budesonide delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy or IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) =1.5g/g. The indication is approved under accelerated approval, Calliditas Therapeutics AB (CALT) said in a statement.

CALT closed Wednesday regular trading at $18.64 up $1.99 or 11.95%. In the after-hours trade, the stock further gained $10.02 or 53.73%.

It has not been established whether Tarpeyo slows kidney function decline in patients with IgAN. Continued approval may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

The company expects that Tarpeyo will be available in the U.S. early in the first quarter of 2022.

IgAN is a rare, progressive autoimmune disease, which has a high unmet need with more than 50% of patients potentially progressing to end-stage renal disease (ESRD).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT